Mode
Text Size
Log in / Sign up

Narrative review discusses cerebral small vessel disease without reporting specific interventions or outcomes

Narrative review discusses cerebral small vessel disease without reporting specific interventions…
Photo by Robina Weermeijer / Unsplash
Key Takeaway
Note that this narrative review lacks specific intervention or outcome data for cerebral small vessel disease.

This publication is a narrative review focused on the topic of cerebral small vessel disease. The source does not report a specific study phase, population, or setting for the evidence presented. No interventions, comparators, or primary outcomes are explicitly detailed within the provided text.

The authors do not synthesize quantitative data, pooled effect sizes, or specific safety profiles. Adverse events, serious adverse events, and tolerability are not reported in the available information. The review does not establish causality or provide specific follow-up durations.

Limitations acknowledged by the authors are not detailed in the input. Funding sources and potential conflicts of interest are not reported. The practice relevance of the review is not explicitly stated, and the certainty of the conclusions is not defined.

Clinicians should interpret this source as a general discussion rather than a data-driven guideline. The absence of specific numerical data or trial details limits the ability to apply these findings to specific patient scenarios.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Cerebral small vessel disease (CSVD) is a leading cause of ischemic stroke and vascular cognitive impairment. Despite well-defined neuroimaging features and a substantial clinical burden, the underlying pathological mechanisms of CSVD remain poorly understood, and effective interventions are still lacking. Current human and experimental evidence suggest that endothelial dysfunction and neuroinflammation are closely coupled and may form a mutually reinforcing process in many CSVD-relevant settings. This review synthesizes available evidence into a working framework in which vascular risk factors promote endothelial phenotypic switching and blood-brain barrier (BBB) dysfunction, thereby facilitating neuroinflammatory activation. Pericytes, astrocytes, and microglia within the neurovascular unit can then amplify barrier injury and inflammatory signaling through context-dependent feedback interactions, including matrix metalloproteinase-mediated proteolysis. In turn, the chronic inflammatory milieu may sustain persistent endothelial dysfunction or alter endothelial responsiveness to subsequent inflammatory stimuli, potentially allowing pathological processes to continue even after the original triggers are attenuated. Based on this evidence-guided framework, we also evaluate therapeutic strategies directed at distinct nodes of the endothelial dysfunction-neuroinflammation network.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.